These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 8571479)

  • 1. [Changes in the picture of chronic diseases on long-term hemodialysis treatment].
    von Appen K; Ivanovich P; Klinkmann H; Stetsiuk E
    Urol Nefrol (Mosk); 1995; (5):25-7. PubMed ID: 8571479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Beta 2-microglobulin--its role in renal failure and hemodialysis therapy].
    Czyz W; Szepietowski T
    Postepy Hig Med Dosw; 1992; 46(2):209-38. PubMed ID: 1470582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Beta 2-microglobulin-induced amyloidosis. A new complication of long-term hemodialysis].
    Ritz E; Bommer J; Zeier M
    Dtsch Med Wochenschr; 1988 Feb; 113(5):190-6. PubMed ID: 3276494
    [No Abstract]   [Full Text] [Related]  

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyloidosis in patients with end-stage renal failure: uraemia associated or dialysis related?
    Davison AM
    Contrib Nephrol; 1995; 113():92-100. PubMed ID: 7712726
    [No Abstract]   [Full Text] [Related]  

  • 6. Are biocompatible membranes superior for hemodialysis therapy?
    van Ypersele de Strihou C
    Kidney Int Suppl; 1997 Nov; 62():S101-4. PubMed ID: 9350694
    [No Abstract]   [Full Text] [Related]  

  • 7. beta 2-microglobulin and amyloidosis: who is at risk?
    Davison AM
    Nephrol Dial Transplant; 1995; 10 Suppl 10():48-51. PubMed ID: 8825433
    [No Abstract]   [Full Text] [Related]  

  • 8. [Mediators of amyloidogenesis and cytokines in dialysis-related amyloidosis].
    Rysavá R; Merta M; Tesar V; Lachmanová J; Sulková S; Bláha J
    Cas Lek Cesk; 2002 Apr; 141(8):244-7. PubMed ID: 12038073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concentration of plasma middle molecular weight substances and clinical condition of patients undergoing short-time regular dialysis treatment.
    Válek A; Dzúrik R; Spustová V; Válková D
    Artif Organs; 1981; 4 Suppl():173-6. PubMed ID: 7295088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rheological properties of red blood cells (including reticulocytes) in patients with chronic renal disease.
    Nowak E; Wyrwicz G; Dabrowski Z; Smoleńiski O; Spodaryk K
    Clin Hemorheol Microcirc; 1999; 21(2):87-94. PubMed ID: 10599591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The hemodialysis membranes: a historical perspective, current state and future prospect.
    Cheung AK; Leypoldt JK
    Semin Nephrol; 1997 May; 17(3):196-213. PubMed ID: 9165649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant neoplasms in long-term hemodialysis patients.
    Olusegun Fayemi A; Ali M
    J Med Soc N J; 1979 Jul; 76(7):497-500. PubMed ID: 289847
    [No Abstract]   [Full Text] [Related]  

  • 13. First clinical experience with an adjunctive hemoperfusion device designed specifically to remove beta(2)-microglobulin in hemodialysis.
    Ronco C; Brendolan A; Winchester JF; Golds E; Clemmer J; Polaschegg HD; Muller TE; La Greca G ; Levin NW
    Blood Purif; 2001; 19(2):260-3. PubMed ID: 11150821
    [No Abstract]   [Full Text] [Related]  

  • 14. Cutaneous and lingual papules as a sign of beta 2 microglobulin-derived amyloidosis in a long-term hemodialysis patient.
    Uenotsuchi T; Imafuku S; Nagata M; Kiryu H; Morita K; Koga T; Furue M
    Eur J Dermatol; 2003; 13(4):393-5. PubMed ID: 12948922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The analysis of plasma beta 2-microglobulin concentration in patients with chronic renal failure treated by hemodialysis].
    Król Z; Morawska Z
    Pediatr Pol; 1996 Feb; 71(2):121-5. PubMed ID: 8966077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of high-flux hemodialysis on dialysis-associated amyloidosis.
    Ayli M; Ayli D; Azak A; Yüksel C; Atilgan G; Dede F; Akalin T; Abayli E; Camlibel M
    Ren Fail; 2005; 27(1):31-4. PubMed ID: 15717632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Renal replacement therapy by hemodialysis: an overview].
    Jacobs C
    Nephrol Ther; 2009 Jul; 5(4):306-12. PubMed ID: 19481513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Action of middle molecules from chronic renal insufficiency treated by hemodialysis on mitochondrial respiration.
    Rinaudo JB; Gallice P; Crevat A; Saingra S; Murisasco A
    Biomedicine; 1979 Oct; 30(4):215-8. PubMed ID: 534675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uraemic itching: do polymethylmethacrylate dialysis membranes play a role?
    Aucella F; Vigilante M; Gesuete A; Maruccio G; Specchio A; Gesualdo L
    Nephrol Dial Transplant; 2007 Jul; 22 Suppl 5():v8-12. PubMed ID: 17586845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dialysis-related amyloidosis: late finding or hidden epidemic?
    Dember LM; Jaber BL
    Semin Dial; 2006; 19(2):105-9. PubMed ID: 16551286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.